Outcome in renal AL amyloidosis after chemotherapy

Journal of Clinical Oncology

Volumn 29, Issue 6, 2011, Pages 674-681

  Pinney, Jennifer H ^a   Lachmann, Helen J ^a   Bansi, Loveleen ^a   Wechalekar, Ashutosh D ^a   Gilbertson, Janet A ^a   Rowczenio, Dorota ^a   Sattianayagam, Prayman T ^a   Gibbs, Simon D J ^a   Orlandi, Emanuela ^a   Wassef, Nancy L ^a   Bradwell, Arthur R ^a   Hawkins, Philip N ^a   Gillmore, Julian D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CHEMOTHERAPY; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIALYSIS; DISEASE COURSE; FEMALE; FREE LIGHT CHAIN; GASTROINTESTINAL HEMORRHAGE; GRAFT SURVIVAL; HUMAN; INFECTION; KIDNEY AMYLOIDOSIS; KIDNEY TRANSPLANTATION; LIGHT CHAIN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

AMYLOIDOSIS; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; KAPLAN-MEIER ESTIMATE; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 79952139728     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.30.5235     Document Type: Article

References (29)

1. Merlini G, Bellotti V: Molecular mechanisms of amyloidosis. N Engl J Med 349:583-596, 2003 (Pubitemid 36951371)
2. Pepys MB: Pathogenesis, diagnosis and treatment of systemic amyloidosis. Philos Trans R Soc Lond B Biol Sci 356:203-210, 2001
3. Dember LM: Amyloidosis-associated kidney disease. J Am Soc Nephrol 17:3458-3471, 2006
4. Kyle RA, Greipp PR, O'Fallon WM: Primary systemic amyloidosis: Multivariate analysis for prognostic factors in 168 cases. Blood 68:220-224, 1986 (Pubitemid 16033633)
5. Kyle RA, Gertz MA, Greipp PR, et al: A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 336:1202-1207, 1997 (Pubitemid 27183649)
6. Comenzo RL, Vosburgh E, Falk RH, et al: Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: Survival and responses in 25 patients. Blood 91:3662-3670, 1998 (Pubitemid 28225733)
7. Lachmann HJ, Gallimore R, Gillmore JD, et al: Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 122:78-84, 2003 (Pubitemid 36819341)
8. Palladini G, Perfetti V, Obici L, et al: Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 103:2936-2938, 2004 (Pubitemid 38451663)
9. Skinner M, Sanchorawala V, Seldin DC, et al: High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: An 8-year study. Ann Intern Med 140:85-93, 2004
10. Merlini G, Stone MJ: Dangerous small B-cell clones. Blood 108:2520-2530, 2006
11. Wechalekar AD, Hawkins PN, Gillmore JD: Perspectives in treatment of AL amyloidosis. Br J Haematol 140:365-377, 2008
12. Kyle RA, Gertz MA: Primary systemic amyloidosis: Clinical and laboratory features in 474 cases. Semin Hematol 32:45-59, 1995 (Pubitemid 24370135)
13. Dubrey SW, Cha K, Anderson J, et al: The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 91:141-157, 1998 (Pubitemid 28102667)
14. Gertz MA, Comenzo R, Falk RH, et al: Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 79:319-328, 2005
15. Leung N, Dispenzieri A, Lacy MQ, et al: Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation. Clin J Am Soc Nephrol 2:440-444, 2007
16. Gertz MA, Leung N, Lacy MQ, et al: Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. Nephrol Dial Transplant 24: 3132-3137, 2009
17. Dember LM, Sanchorawala V, Seldin DC, et al: Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease. Ann Intern Med 134:746-753, 2001 (Pubitemid 32402067)
18. Bergesio F, Ciciani AM, Manganaro M, et al: Renal involvement in systemic amyloidosis: An Italian collaborative study on survival and renal outcome. Nephrol Dial Transplant 23:941-951, 2008
19. Esteve V, Almirall J, Ponz E, et al: Renal involvement in amyloidosis: Clinical outcomes, evolution and survival. Nefrologia 26:212-217, 2006
20. Bollée G, Guery B, Joly D, et al: Presentation and outcome of patients with systemic amyloidosis undergoing dialysis. Clin J Am Soc Nephrol 3:375-381, 2008
21. Leung N, Griffin MD, Dispenzieri A, et al: Living donor kidney and autologous stem cell transplantation for primary systemic amyloidosis (AL) with predominant renal involvement. Am J Transplant 5:1660-1670, 2005 (Pubitemid 40910448)
22. Lachmann HJ, Booth DR, Booth SE, et al: Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 346:1786-1791, 2002 (Pubitemid 34586914)
23. Hawkins PN, Lavender JP, Pepys MB: Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med 323:508-513, 1990 (Pubitemid 20260051)
24. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 39:S1-S266, 2002
25. Palladini G, Campana C, Klersy C, et al: Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 107:2440-2445, 2003 (Pubitemid 36605226)
26. Hutchison CA, Harding S, Hewins P, et al: Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol 3:1684-1690, 2008
27. Dispenzieri A, Zhang L, Katzmann JA, et al: Appraisal of immunoglobulin free light chain as a marker of response. Blood 111:4908-4915, 2008
28. Dispenzieri A, Lacy MQ, Katzmann JA, et al: Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 107:3378-3383, 2006
29. Hartmann A, Holdaas H, Fauchald P, et al: Fifteen years' experience with renal transplantation in systemic amyloidosis. Transpl Int 5:15-18, 1992